2 terminated, 1 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow INO 1001: new trials by email Literature Review of INO 1001 trials Research Report on INO 1001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma INO-1001, temozolomide - Melanoma | Phase 1 | Terminated | Genentech, Inc. | 39 | 2005-10-01 | 2009-03-11 |
| A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass INO-1001 - Heart Diseases, Postoperative Complications | Phase 2 | Terminated | Inotek Pharmaceuticals Corporation | 162 | 2005-10-01 | 2015-03-25 |
| A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention INO-1001 - Acute Myocardial Infarction | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 40 | 2004-01-01 | 2006-11-29 |
Deafness, Autosomal Recessive 53 (1) · Heart Diseases (1) · Melanoma (1) · Myocardial Infarction (1) · Postoperative Complications (1)
Inotek Pharmaceuticals Corporation (2) · Genentech, Inc. (1)
Israel (2) · United States (2) · Australia (1) · India (1)